PARAMOUNT trial
PARAMOUNT Trial is a clinical trial that was conducted to evaluate the efficacy and safety of Pemetrexed as a maintenance therapy for patients with advanced Non-small cell lung cancer (NSCLC) who have not progressed after initial chemotherapy. The trial was a phase III, double-blind, placebo-controlled study.
Overview[edit]
The PARAMOUNT trial was designed to assess the benefits of maintenance therapy with Pemetrexed in patients with advanced NSCLC who had not progressed after four cycles of Pemetrexed-cisplatin induction therapy. The primary endpoint of the trial was progression-free survival, while secondary endpoints included overall survival, response rate, and safety.
Results[edit]
The results of the PARAMOUNT trial showed that maintenance therapy with Pemetrexed significantly improved progression-free survival in patients with advanced NSCLC. The trial also demonstrated a trend towards improved overall survival, although this was not statistically significant.
Implications[edit]
The findings of the PARAMOUNT trial have important implications for the management of patients with advanced NSCLC. They suggest that maintenance therapy with Pemetrexed may be a viable option for these patients, potentially improving their quality of life and survival outcomes.
See Also[edit]
References[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
-
PARAMOUNT trial informed consent document
-
Diagram of human lungs
